{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:08:56Z","timestamp":1790906936036,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.cgh.2006.11.001","type":"journal-article","created":{"date-parts":[[2007,2,13]],"date-time":"2007-02-13T07:07:54Z","timestamp":1171350474000},"page":"215-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of Subjects With Active Crohn\u2019s Disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Bruce","family":"Yacyshyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Y.","family":"Chey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Wedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie Z.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2006.11.001_bib1","series-title":"Inflammatory bowel disease: from bench to bedside","first-page":"296","article-title":"Clinical features and complications of Crohn\u2019s disease","author":"Levine","year":"1993"},{"key":"10.1016\/j.cgh.2006.11.001_bib2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for Crohn\u2019s disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Eng J Med"},{"key":"10.1016\/j.cgh.2006.11.001_bib3","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Eng J Med"},{"key":"10.1016\/j.cgh.2006.11.001_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4049\/jimmunol.137.1.245","article-title":"Induction by IL-1 and interferon: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1)","volume":"137","author":"Dustin","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2006.11.001_bib5","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4049\/jimmunol.137.4.1270","article-title":"A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1","volume":"137","author":"Rothlein","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2006.11.001_bib6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/331624a0","article-title":"ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM","volume":"331","author":"Simmons","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2006.11.001_bib7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0092-8674(87)90104-8","article-title":"Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen-1 (LFA-1)","volume":"51","author":"Marlin","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.cgh.2006.11.001_bib8","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1083\/jcb.111.6.3129","article-title":"ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b\/CD18)","volume":"111","author":"Diamond","year":"1990","journal-title":"J Cell Biol"},{"key":"10.1016\/j.cgh.2006.11.001_bib9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0092-8674(91)90279-8","article-title":"Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity","volume":"67","author":"Butcher","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.cgh.2006.11.001_bib10","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood.V78.8.2089.2089","article-title":"Monoclonal antibodies to leukocyte chemoattractant-stimulated neutrophil transendothelial migration in vitro","volume":"78","author":"Furie","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.cgh.2006.11.001_bib11","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.4049\/jimmunol.147.9.2913","article-title":"Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes","volume":"147","author":"Oppenheimer-Marks","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2006.11.001_bib12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/338512a0","article-title":"Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells","volume":"338","author":"Altmann","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2006.11.001_bib13","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.4049\/jimmunol.144.12.4579","article-title":"The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells","volume":"144","author":"Van Seventer","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2006.11.001_bib14","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.4049\/jimmunol.146.6.1773","article-title":"The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation: contributions of adhesion and co-activation","volume":"146","author":"Kuhlman","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2006.11.001_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/eji.1830180423","article-title":"Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity","volume":"18","author":"Makgoba","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.cgh.2006.11.001_bib16","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood.V84.7.2261.2261","article-title":"Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium","volume":"84","author":"Allavena","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.cgh.2006.11.001_bib17","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.4049\/jimmunol.163.9.5029","article-title":"Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration","volume":"163","author":"Ding","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2006.11.001_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.1780390315","article-title":"Regulation of adhesion molecule expression by human synovial microvascular endothelial cells in vitro","volume":"39","author":"To","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"Suppl 57","key":"10.1016\/j.cgh.2006.11.001_bib19","first-page":"16","article-title":"The role of tumor necrosis factor in health and disease","volume":"26","author":"Beutler","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2006.11.001_bib20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/gut.36.5.724","article-title":"Adhesion molecules in inflammatory bowel disease","volume":"36","author":"Jones","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2006.11.001_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2249.1990.tb05477.x","article-title":"Differential upregulation of intercellular adhesion molecule-1 in coeliac disease","volume":"82","author":"Sturgess","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cgh.2006.11.001_bib22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000013505","article-title":"Correlations among expression of glomerular intercellular adhesion molecule 1 (ICAM-1), levels of serum soluble ICAM-1, and renal histopathology in patients with IgA nephropathy","volume":"19","author":"Nguyen","year":"1999","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.cgh.2006.11.001_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/096120339900800603","article-title":"Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro","volume":"8","author":"Papa","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.cgh.2006.11.001_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s004030050317","article-title":"Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis","volume":"290","author":"Ackermann","year":"1998","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.cgh.2006.11.001_bib25","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/00005072-199655100-00006","article-title":"Distribution of immunoglobulin superfamily members ICAM-1, -2, -3 and the \u03b22 integrin LFA-1 in multiple sclerosis","volume":"55","author":"Bo","year":"1996","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.cgh.2006.11.001_bib26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0016-5085(98)70418-4","article-title":"A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn\u2019s disease","volume":"114","author":"Yacyshyn","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2006.11.001_bib27","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1046\/j.1365-2036.2002.01341.x","article-title":"Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn\u2019s disease","volume":"16","author":"Yacyshyn","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2006.11.001_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/108729003764097340","article-title":"Prediction of clinical responses in a simulated phase 3 trial of Crohn\u2019s patients administered the antisense phosphorothiloate oligonucleotide ISIS 2302: comparison of proposed dosing regimens","volume":"13","author":"Yu","year":"2003","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.cgh.2006.11.001_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/gut.51.1.30","article-title":"Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn\u2019s disease","volume":"51","author":"Yacyshyn","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2006.11.001_bib30","first-page":"409","article-title":"Noncompartmental analysis based on statistical moment theory","volume":"Volume 15","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.cgh.2006.11.001_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/abio.2002.5576","article-title":"Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma","volume":"304","author":"Yu","year":"2002","journal-title":"Anal Biochem"},{"key":"10.1016\/j.cgh.2006.11.001_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/adc.73.4.354","article-title":"Indications for investigation of chronic gastrointestinal symptoms","volume":"73","author":"Beattie","year":"1995","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cgh.2006.11.001_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/pgmj.2003.013722","article-title":"Management of inflammatory bowel disease","volume":"80","author":"Nayar","year":"2004","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.cgh.2006.11.001_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0009-8981(85)90219-0","article-title":"C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders","volume":"148","author":"Shine","year":"1985","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cgh.2006.11.001_bib35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00042737-200204000-00013","article-title":"A new highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders","volume":"14","author":"Poullis","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2006.11.001_bib36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism","volume":"37","author":"Louis","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2006.11.001_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","article-title":"Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn\u2019s disease","volume":"19","author":"Louis","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2006.11.001_bib38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn\u2019s disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1016\/j.cgh.2006.11.001_bib39","first-page":"A239","article-title":"Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn\u2019s disease (abstract)","volume":"52","author":"Rutgeerts","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2006.11.001_bib40","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2003.035253","article-title":"CDP571, a humanized monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn\u2019s disease: a randomised, double blind, placebo controlled trial","volume":"53","author":"Sandborn","year":"2004","journal-title":"Gut"},{"issue":"Suppl","key":"10.1016\/j.cgh.2006.11.001_bib41","first-page":"A745","article-title":"Certolizumab Pegol administered subcutaneously is effective and well tolerated in patients with active Crohn\u2019s disease: results from a 26-week, placebo controlled Phase III study (PRECiSE1) (abstract)","author":"Sandborn","year":"2006","journal-title":"Gastroenterology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356506011451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356506011451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:59:01Z","timestamp":1761541141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356506011451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S1542356506011451"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2006.11.001","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of Subjects With Active Crohn\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2006.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}